Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
Quince Therapeutics, Inc. (QNCX)
Company Research
Source: Business Wire
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the poster presentation at the 53rd Child Neurology Society (CNS) Annual Meeting of safety data from its prior Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem; #IEDAT-02-2015/NCT02770807) clinical trial. The objective of the data analysis was to evaluate treatment-emergent adverse events (TEAEs) in patients with Ataxia-Telangiectasia (A-T) treated with the company’s lead asset, EryDex (intra-erythrocyte dexamethasone sodium phosphate), for one year compared to placebo control.Key findings reported in the poster presentation, titled Treatment-Emergent Adverse Events (TEAEs) in Children With Ataxia-Telangiectasia Treated for One Year With Intra-Erythrocyte Dexamethasone Sodium Phosphate (EryDex), include:EryDex treatment was generall
Show less
Read more
Impact Snapshot
Event Time:
QNCX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QNCX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QNCX alerts
High impacting Quince Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
QNCX
News
- Quince Therapeutics files for $200M mixed securities shelf [Seeking Alpha]Seeking Alpha
- Quince Therapeutics, Inc. (NASDAQ: QNCX) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $9.00 price target on the stock.MarketBeat
- Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial ResultsBusiness Wire
- Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia ResearchBusiness Wire
- Quince Therapeutics, Inc. (NASDAQ: QNCX) is now covered by analysts at Maxim Group. They set a "buy" rating and a $6.00 price target on the stock.MarketBeat
QNCX
Sec Filings
- 12/18/24 - Form S-3
- 11/14/24 - Form SC
- 11/14/24 - Form 8-K
- QNCX's page on the SEC website